| 强心康颗粒治疗慢性心力衰竭的临床研究 |
| |
| 引用本文： | 刘淑荣,张晓华,钱锋,孙颖,翟颖,于清华. 强心康颗粒治疗慢性心力衰竭的临床研究[J]. 中华全科医学, 2019, 17(3): 364-366. DOI: 10.16766/j.cnki.issn.1674-4152.000682 |
| |
| 作者姓名： | 刘淑荣 张晓华 钱锋 孙颖 翟颖 于清华 |
| |
| 作者单位： | 吉林省中医药科学院第一临床医院心病科, 吉林 长春 130021 |
| |
| 基金项目： | 吉林省科技厅重点科技攻关计划项目(20150204059YY) |
| |
| 摘 要： | 目的 评价强心康颗粒治疗慢性心力衰竭的临床疗效,为研发院内制剂提供临床病例资料。 方法 选择2015年1月-2017年5月吉林省中医药科学院第一临床医院心病科慢性心力衰竭患者200例,随机分为治疗组、对照组,每组各100例。2组患者在西药治疗的基础上,治疗组加用强心康颗粒1袋(10 g),每日2次口服,疗程为8周。于治疗前后观察2组患者6分钟步行距离、血浆中NT-proBNP浓度、中医证候积分,并评价其临床疗效。 结果 在中医证候疗效方面,治疗组优于对照组,但2组比较差异无统计学意义(P>0.05),治疗组与对照组6分钟步行距离均延长,治疗组自身前后比较差异有统计学意义(P<0.05),对照组自身前后比较差异无统计学意义(P>0.05);治疗组与对照组疗后比较差异有统计学意义(P<0.05)。2组患者血浆NT-proBNP浓度均有不同程度的降低,治疗组治疗前后比较差异有统计学意义(P<0.05),对照组自身前后比较差异无统计学意义(P>0.05);组间疗后比较,2组差异无统计学意义(P>0.05)。 结论 对于慢性心力衰竭患者,在西药规范化治疗基础上加用中药强心康颗粒,能够减轻心衰患者的临床症状、增加患者6分钟步行距离,降低血浆中NT-proBNP浓度,提高患者生活质量,适合研发院内制剂,可在临床广泛应用。
|
| 关 键 词： | 慢性心力衰竭 中医药疗法 强心康颗粒 临床疗效 |
| 收稿时间： | 2018-01-20 |
Clinical study of Qiangxinkang granule in the treatment of chronic heart failure |
| |
| Affiliation: | Department of Cardiology, the First Clinical Hospital, Jilin Academy of Traditional Chinese Medicine, Changchun, Jilin 130021, China |
| |
| Abstract: | Objective To evaluate the clinical efficacy of Qiangxinkang Granule in the treatment of chronic heart failure and provide clinical case data for the development of hospital preparations. Methods Total 200 patients with chronic heart failure were randomly divided into treatment group and control group, with 100 cases in each group. On the basis of western medicine treatment, the treatment group received additional Qiangxinkang granules (1 bag, 10 g), twice a day, for 8 weeks. Before and after the treatment, the 6-minute walking distance, plasma NT-proBNP concentration, TCM syndromes score were observed and the clinical efficacy was evaluated. Results The curative effect of TCM syndrome: by rank sum test, the treatment group was superior to the control group, but there was no statistical difference between the two groups (P>0.05). In 6-minute walking distance, the walking distance after the treatment in both groups was prolonged. In the treatment group, it was improved significantly (P<0.05), however in the control group, it was not significant (P>0.05). After the treatment, there was significant difference between the treatment group and the control group (P<0.05). The level of plasma NT-proBNP after the treatment decreased in both group to varying degrees, significantly in the treatment group (P<0.05). After the treatment, there was no statistical difference in the level of plasma NT-proBNP between the two groups (P>0.05). Conclusion For patients with chronic heart failure, the addition of Qiangxinkang granule to the standardized treatment of western medicine can alleviate the clinical symptoms of patients with heart failure, increase the walking distance of patients with heart failure for 6 minutes, reduce the concentration of NT-proBNP in plasma, and improve the quality of life of patients. The result provides a reference for the research and development of hospital preparations, and worth to be widely used in clinic. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载免费的PDF全文 |
|
